Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.

ABSTRACT:

Background

Studies on the efficacy of peanut sublingual immunotherapy (SLIT) are limited. The durability of desensitization after SLIT has not been well described.

Objective

We sought to evaluate the efficacy and safety of 4-mg peanut SLIT and persistence of desensitization after SLIT discontinuation.

Methods

Challenge-proven peanut-allergic 1- to 11-year-old children were treated with open-label 4-mg peanut SLIT for 48 months. Desensitization after peanut SLIT was assessed by a 5000-mg double-blind, placebo-controlled food challenge (DBPCFC). A novel randomly assigned avoidance period of 1 to 17 weeks was followed by the DBPCFC. Skin prick test results immunoglobulin levels, basophil activation test results, T_H1, T_H2, and IL-10 cytokines were me

SUBMITTER: Kim EH 

PROVIDER: S-EPMC10257751 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature